{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-21-022843","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2021-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.729921+00:00","generated_at":"2026-06-29T00:42:15.176385+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Genprex appoints Dr. Mark Berger as CMO, Dr. Hemant Kumar as CTO; COO Redman's role reduced","bullets":["Mark Berger, MD appointed Chief Medical Officer; Hemant Kumar, PhD appointed Chief Manufacturing and Technology Officer.","Michael Redman, EVP and COO, no longer oversees clinical and manufacturing operations; company in discussions for alternate role.","Appointments effective September 2021 as disclosed in prior 8-K filed September 28, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-21-022843","json":"https://secwatch.observer/filing/0001437749-21-022843.json","markdown":"https://secwatch.observer/filing/0001437749-21-022843.md","text":"https://secwatch.observer/filing/0001437749-21-022843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774921022843/0001437749-21-022843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774921022843/gnpx20210929_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T00:42:15.176385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e274511a39","claim":"Michael Redman changed role as Executive Vice President and Chief Operating Officer at Genprex, Inc..","evidence_excerpt":"With these new appointments, Michael Redman, the Company’s Executive Vice President and Chief Operating Officer is no longer overseeing the Company’s clinical and manufacturing operations.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774921022843/0001437749-21-022843-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"reassigned"},{"label":"Role","value":"Executive Vice President and Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"ea554bc00f","claim":"Hemant Kumar was appointed as Chief Manufacturing and Technology Officer at Genprex, Inc..","evidence_excerpt":"the Company has appointed Mark Berger, MD and Hemant Kumar, PhD as its new Chief Medical Officer and new Chief Manufacturing and Technology Officer, respectively.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774921022843/0001437749-21-022843-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Manufacturing and Technology Officer"}],"fact_type":"executive_change"},{"claim_id":"ea72697f9d","claim":"Mark Berger was appointed as Chief Medical Officer at Genprex, Inc..","evidence_excerpt":"the Company has appointed Mark Berger, MD and Hemant Kumar, PhD as its new Chief Medical Officer and new Chief Manufacturing and Technology Officer, respectively.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774921022843/0001437749-21-022843-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}